Skip to content
Assyro AI
Orange Book drug · Brand (NDA)

Fludeoxyglucose F18

Fludeoxyglucose F-18

DiscontinuedRLDNDA 020306 2 strengths Downstate Clincl
Approved
Aug 19, 1994
Strengths
2
Listed patents
0
Applications
44

What does the FDA Orange Book show for Fludeoxyglucose F18?

Fludeoxyglucose F18 contains Fludeoxyglucose F-18 and appears in 44 FDA Orange Book applications. NDA 020306 is the lead filing, with 2 presentations shown in detail; the other exact-name filings are listed separately. The page preserves strength, dosage form, route, status, RLD/RS, TE, patent, and exclusivity facts. Clinical labeling requires an exact application-matched source.

FDA applications
44; lead NDA 020306

Every filing shown uses the exact FDA product name; the lead filing supplies the detailed presentation view.

Lead application holder
Downstate Clinical Pet Center

The listed applicant holds the FDA application; this field does not establish the product manufacturer.

Product presentations
2

Each FDA product number remains tied to its own strength, dosage form, route, and status.

Marketing categories
Discontinued

Orange Book marketing categories do not establish real-time inventory or commercial availability.

Reference roles
RLD

RLD and RS designations are presentation-specific, not inferred from the trade name.

TE codes
None posted

Therapeutic-equivalence codes apply only within the matching Orange Book product heading.

Listed patents
0

A zero means none appear in this snapshot, not that no patent rights exist.

Exclusivity records
0

FDA exclusivity and listed patent protection are distinct regulatory concepts.

Sourced from the official FDA Orange Book data file · snapshot refreshed

FDA product-presentation matrix

Every product number in this exact application
Every FDA product presentation under this application, with strength, dosage form and route, marketing status, therapeutic-equivalence code, and reference role.
ProductStrengthDosage form / routeMarketing statusTE codeReference role
0014-40mCi/MLINJECTABLEINJECTIONDiscontinuedNone posted
RLD
0024-90mCi/MLINJECTABLEINJECTIONDiscontinuedNone posted
RLD

Marketing status, TE code, RLD, and RS are presentation-level fields. Never transfer one product number's designation to another presentation.

Who is responsible for this application?

Application holder is not the same as manufacturer

FDA application holder

Downstate Clinical Pet Center

The Orange Book identifies this organization as the applicant responsible for NDA 020306.

Manufacturer status

Not established by the Orange Book

A product-specific FDA label or NDC source must independently identify a manufacturer, labeler, distributor, packager, repackager, or relabeler. The applicant name is not used as a substitute for that evidence.

Regulatory interpretation

What the record means, and what it does not
FDA marketing status

2 presentations listed as on the Discontinued Drug Product List

A discontinued-list entry does not, by itself, show why marketing stopped or whether FDA determined the product was withdrawn for safety or effectiveness.

Therapeutic equivalence

No TE code is posted for this application

No TE code does not mean FDA found the product ineffective or non-equivalent. FDA generally publishes TE evaluations for multisource prescription products; single-source and some other products may have no code.

Patent & exclusivity record

No listed patents or exclusivity records

This means none appear for this application in the current Orange Book files. It is not a freedom-to-operate opinion and does not rule out unlisted patents, regulatory barriers, or product-specific rights.

Same-ingredient landscape

0 other ANDAs and 0 other NDAs found

0 of the related ANDA applications are not marked discontinued. Sharing an ingredient does not establish pharmaceutical or therapeutic equivalence; strength, dosage form, route, and TE group still matter.

Which products are meaningfully comparable?

Exact ingredient + dosage form + route cohorts

NDA 020306 appears in 1 comparison cohort. These groups narrow the same-ingredient landscape, but strength and TE code must still match before interpreting therapeutic equivalence.

Injectable · Injection

Fludeoxyglucose F-18

1 application
Product rows
2
Active applications
0
Active with AB row
0

Why are clinical sections unavailable?

Exact application-label matching status
Exact source match queuedQueue NDA-020306

No exact application-level FDA or DailyMed label match has been reviewed for this application. Approved uses, dosing, warnings, adverse reactions, and clinical evidence remain unavailable rather than being inherited from a related brand, generic, or ingredient record.

Until an exact application match passes human review, this page intentionally omits approved uses, dosing, warnings, adverse reactions, mechanism, and clinical-study summaries. It never inherits those claims from an RLD, brand, generic, or same-ingredient product.

Strengths & dosage forms

2 approved presentations · NDA 020306
RLDDiscontinued
Strength
4-40mCi/ML
Dosage form
INJECTABLE
Route
INJECTION
Marketing status
Discontinued

Key dates

Approval, patents, exclusivity

  1. Approval

    FDA approval date of this drug product.

    32 yr 5 mo ago

  2. Today

Pharmaceutical detail

FDA product record

Active ingredient

FLUDEOXYGLUCOSE F-18

Strength

4-40mCi/ML

Dosage form

INJECTABLE

Route

INJECTION

TE code

Not listed

Application

NDA 020306

Product number

001

Marketing status

Discontinued

Reference listed drug (RLD)

Yes

Reference standard (RS)

No

Listed patents

Orange Book patent file

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Other FDA applications for Fludeoxyglucose F18

43 additional filings · 41 generic

The FDA has approved 44 separate applications under this product name. Each row is one application: a distinct applicant and approval for the same drug.

Other FDA applications approved under the product name Fludeoxyglucose F18, with applicant, approval date, number of strengths, therapeutic-equivalence code, and marketing status.
ApplicationApplicantApprovedStrengthsTE codeStatus
NDA 021768Weill Medcl CollAug 05, 20041—Discontinued
NDA 021870FeinsteinAug 19, 20052—Discontinued
ANDA 079086PetnetFeb 25, 20111APPrescription
ANDA 203603Cardinal Health 414Sep 27, 20182APPrescription
ANDA 203771Queen Hamamatsu PetAug 31, 20151APPrescription
ANDA 203811Ucla BiomedicalJun 27, 20131APPrescription
ANDA 203246Univ Tx Md AndersonJan 13, 20142—Prescription
ANDA 203591SofieAug 31, 20151APPrescription
ANDA 203612McprfAug 05, 20131APPrescription
ANDA 203664Pharmalogic HldgsFeb 04, 20141APPrescription
ANDA 203665SofieFeb 14, 20131—Discontinued
ANDA 203709WisconsinOct 23, 20131—Discontinued
ANDA 203710Biomedcl Res FdnMay 01, 20151APPrescription
ANDA 203736Midwest MedclNov 19, 20151—Discontinued
ANDA 2037783d Imaging DrugOct 30, 20151APPrescription
ANDA 203801Trustees Univ PaOct 29, 20141APPrescription
ANDA 203816Brigham WomensOct 30, 20141APPrescription
ANDA 203837Biomedcl Res FdnMay 01, 20151APPrescription
ANDA 203902Ucsf RodiopharmMay 09, 20141APPrescription
ANDA 203904Methodist Hosp ResApr 23, 20151APPrescription
ANDA 203911NukemedApr 22, 20151—Discontinued
ANDA 203920Jubilant DraximageJun 23, 20151APPrescription
ANDA 203935Wusm CyclotronFeb 05, 20141APPrescription
ANDA 203937Hot Shots Nm LLCOct 30, 20141—Discontinued
ANDA 203942Kreitchman Pet CtrApr 11, 20161APPrescription
ANDA 203946Essential IsotopesFeb 05, 20141—Discontinued
ANDA 203990Uihc Pet ImagingAug 06, 20141APPrescription
ANDA 203994NorthlandFeb 04, 20151—Prescription
ANDA 204264PharmalogicDec 18, 20141APPrescription
ANDA 204333Ma General HospSep 25, 20141APPrescription
ANDA 204385Childrens Hosp MiOct 29, 20141APPrescription
ANDA 204463SofieOct 21, 20141APPrescription
ANDA 204472Mips CrfSep 11, 20151APPrescription
ANDA 204498Univ Utah CyclotronJun 23, 20151APPrescription
ANDA 204512Ncm USA Bronx LLCJan 07, 20151APPrescription
ANDA 204525Isologic InnovativeOct 29, 20141APPrescription
ANDA 204531Univ MichiganJul 17, 20151APPrescription
ANDA 204546Precision NuclearApr 07, 20151APPrescription
ANDA 204759Kettering MedctrOct 27, 20151APPrescription
ANDA 208679Mem Sloan-ketteringDec 08, 20161—Discontinued
ANDA 209341Univ Southern CaDec 16, 20201APPrescription
ANDA 210265Univ Tx Sw MedctrFeb 06, 20201—Discontinued
ANDA 216125BamfMar 11, 20251APPrescription

Active-ingredient family

Brand + generics

This is a reference-listed drug (RLD), the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

No other applications share this active ingredient.

View full Fludeoxyglucose F-18 family

How to use this record responsibly

Scope, limitations, and primary sources

What to verify before making a decision

  • The applicant is the holder of legal responsibility for the application; the Orange Book does not establish that the applicant manufactured or currently markets every listed product.
  • RX, OTC, and discontinued are FDA listing categories, not real-time pharmacy inventory or commercial-availability data.
  • Therapeutic equivalence applies only within the matching ingredient, dosage form, route, strength, and TE-code group; same ingredient alone is insufficient.
  • Listed patent and exclusivity dates are regulatory intelligence, not legal advice, a freedom-to-operate analysis, or a reliable generic-launch forecast.
  • The Orange Book is not prescribing information and does not provide indications, dosing, contraindications, adverse reactions, recalls, or current safety communications.

Official FDA references

Data shown here is normalized for search and comparison. When a regulatory, substitution, launch, or legal decision turns on a field, verify it against the current FDA record and the relevant source document.

Fludeoxyglucose F18: frequently asked questions

Approval, therapeutic equivalence, patents, and exclusivity for this drug, from the FDA Orange Book.

Built directly from the FDA Orange Book product, patent, and exclusivity files refreshed Jul 02, 2026, 06:34 PM. Every strength of NDA 020306 is shown on this page. Interpret patents, exclusivity, availability, and therapeutic equivalence using the limitations above.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.

Book a Demo